BACKGROUND: The TNF-α antagonist golimumab is approved for the treatment of ulcerative colitis but not for Crohn's disease (CD). We herein report a case series of 8 difficult-to-treat patients with severe and refractory CD receiving golimumab as an off-label rescue medication and fourth-line anti-TNF agent in our tertiary referral inflammatory bowel disease center. METHODS: We performed a retrospective analysis of clinical, biochemical, and radiological as well as endoscopic parameters. The patients all suffered from severe refractory CD with ongoing symptoms. Moreover, all 8 patients had previously been treated with all 3 other TNF-α antagonists approved for CD in Switzerland (infliximab, adalimumab, and certolizumab pegol) without durable clinical response. RESULTS: Three out of 8 patients showed a primary nonresponse. Among the 5 patients responding after induction, 1 patient showed a loss of response, and in 1 patient, treatment was terminated due to side effects. Three patients have a continuous clinical response under golimumab. We did not observe any severe adverse events during golimumab administration. CONCLUSIONS: A considerable fraction of this highly selected subgroup of difficult-to-treat CD patients responded to golimumab, indicating a promising potential for refractory CD patients, including those with multiple previous anti-TNF exposures.
BACKGROUND: The TNF-α antagonist golimumab is approved for the treatment of ulcerative colitis but not for Crohn's disease (CD). We herein report a case series of 8 difficult-to-treat patients with severe and refractory CD receiving golimumab as an off-label rescue medication and fourth-line anti-TNF agent in our tertiary referral inflammatory bowel disease center. METHODS: We performed a retrospective analysis of clinical, biochemical, and radiological as well as endoscopic parameters. The patients all suffered from severe refractory CD with ongoing symptoms. Moreover, all 8 patients had previously been treated with all 3 other TNF-α antagonists approved for CD in Switzerland (infliximab, adalimumab, and certolizumab pegol) without durable clinical response. RESULTS: Three out of 8 patients showed a primary nonresponse. Among the 5 patients responding after induction, 1 patient showed a loss of response, and in 1 patient, treatment was terminated due to side effects. Three patients have a continuous clinical response under golimumab. We did not observe any severe adverse events during golimumab administration. CONCLUSIONS: A considerable fraction of this highly selected subgroup of difficult-to-treat CD patients responded to golimumab, indicating a promising potential for refractory CD patients, including those with multiple previous anti-TNF exposures.
Authors: Michael Scharl; Pascal Frei; Michael Fried; Gerhard Rogler; Stephan R Vavricka Journal: J Crohns Colitis Date: 2010-10-29 Impact factor: 9.071
Authors: Arthur Kavanaugh; Désirée van der Heijde; Iain B McInnes; Philip Mease; Gerald G Krueger; Dafna D Gladman; Juan Gómez-Reino; Kim Papp; Anna Baratelle; Weichun Xu; Surekha Mudivarthy; Michael Mack; Mahboob U Rahman; Zhenhua Xu; Julie Zrubek; Anna Beutler Journal: Arthritis Rheum Date: 2012-08
Authors: David J Shealy; Ann Cai; Kim Staquet; Audrey Baker; Eilyn R Lacy; Laura Johns; Omid Vafa; George Gunn; Susan Tam; Sarah Sague; Dana Wang; Mike Brigham-Burke; Paul Dalmonte; Eva Emmell; Bill Pikounis; Peter J Bugelski; Honghui Zhou; Bernard J Scallon; Jill Giles-Komar Journal: MAbs Date: 2010-07-01 Impact factor: 5.857
Authors: Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; Zhenhua Xu; John Han; Peter Taylor Journal: Arthritis Rheum Date: 2010-04
Authors: Edward C Keystone; Mark C Genovese; Stephen Hall; Pedro C Miranda; Sang-Cheol Bae; William Palmer; Zhong Wu; Stephen Xu; Elizabeth C Hsia Journal: J Rheumatol Date: 2013-05-15 Impact factor: 4.666
Authors: M Allez; S Vermeire; N Mozziconacci; P Michetti; D Laharie; E Louis; M-A Bigard; X Hébuterne; X Treton; A Kohn; P Marteau; A Cortot; C Nichita; G van Assche; P Rutgeerts; M Lémann; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2010-01 Impact factor: 8.171
Authors: Paul Emery; Roy M Fleischmann; Larry W Moreland; Elizabeth C Hsia; Ingrid Strusberg; Patrick Durez; Peter Nash; Eric Jason B Amante; Melvin Churchill; Won Park; Bernardo Antonio Pons-Estel; Mittie K Doyle; Sudha Visvanathan; Weichun Xu; Mahboob U Rahman Journal: Arthritis Rheum Date: 2009-08
Authors: William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts Journal: Gastroenterology Date: 2013-06-02 Impact factor: 22.682
Authors: Karma Yeshi; Roland Ruscher; Luke Hunter; Norelle L Daly; Alex Loukas; Phurpa Wangchuk Journal: J Clin Med Date: 2020-04-28 Impact factor: 4.241
Authors: Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese Journal: Am J Clin Dermatol Date: 2022-05-24 Impact factor: 6.233